



1st Annual DSEC Member Summit

June 10-11, 2008

Hyatt Regency * Philadelphia, PA

Objectives during Summit

- Identify the topics, areas of shared concern and policies that are important to DSEC members and DSEC objectives or mission
- Discuss or define promising strategies and approaches to managing a holistic drug safety strategy
- Define areas of shared concern amenable to future collaborative projects and/or membership activities
- Determine priorities and alignment of DSEC objectives and activities
- Communicate the existence and importance of the DSEC agenda and mission to the life sciences industry
- Determine best practices and emerging developments that can be enabled by or benefited from DSEC sponsored collaborations and activities
- Improved Drug Safety paradigms and decision making that lead to increased R & D productivity



1st Annual DSEC Member Summit

June 10-11, 2008
Hyatt Regency * Philadelphia, PA

Summit Deliverables

- Presentations and group discussions comparing and contrasting strategies, approaches and methods used in drug safety
- Interactive dialogue and networking to explore and define best practices
- Define & prioritize challenges facing DSEC members
- Discuss potential value of DSEC based collaborative approaches to addressing challenges of drug safety and R&D, e.g., data sharing & evaluation of novel technologies
- Opportunities to share and evaluate contemporary or emerging methods and approaches
- Summary document of findings, opinions and action items

Preliminary Register by April 25 and save \$400!

Inaugural
DSEC Member Summit
Confronting Major Safety Issues of the 21st Century
June 10-11, 2008 • Hyatt Regency at Penn's Landing • Philadelphia, PA

DSEC Advisory Board

- Dr. Jack A. Reynolds
Chairman of the Advisory Board
Drug Safety Executive Council
- Dr. Marc Bornafra
Global Head of Drug Safety Evaluation & Scientific
Site Director for Sciences and Medical Affairs
sanofi-sintelabo
- Dr. Gerald Fisher
Senior Vice President, Office of the President
Wyeth Research
- Dr. Jim Green
Senior Vice President, Preclinical and Clinical
Development Sciences
Eli Lilly
- Dr. Ruth Lightfoot
Vice President, Comparative Biology &
Safety Sciences
Amgen
- Dr. Gregg Lundean
Vice President, Toxicology
Eli Lilly
- Dr. James McDonald
Executive Vice President, Preclinical Development
Schering-Plough
- Dr. Peter Moldeus
Global Vice President, Drug Safety Evaluation
AstraZeneca
- Dr. Thomas Singer
Global Head, Non Clinical Safety
F. Hoffmann-La Roche
- Paul Timpany
Senior Vice President, Safety Assessments
GlaxoSmithKline
- Dr. Herman Van Cauteren
Senior Vice President / Global Head, GPCD
Johnson & Johnson PRD
- Dr. Eckhard von Kautz
Senior Vice President, Global Head of Toxicology
Bayer HealthCare AG

A highly interactive, roundtable format

Featured Presenters

- Dr. Gerald Fisher**, Senior Vice President, Office of the President, Wyeth Research
- Dr. Ruth Lightfoot-Dunn**, Comparative Biology & Safety Sciences, Amgen
- Dr. Peter Moldeus**, Global Vice President, Drug Safety Evaluation, AstraZeneca
- Dr. Jack Reynolds**, Chairman, DSEC Advisory Board
- Dr. Herman Van Cauteren**, Senior Vice President / Global Head, GPCD, Johnson & Johnson PRD

- Improving safety decision making
- More effective project team interactions and drug development strategies
- Improved risk management planning and pharmacovigilance strategies
- Demonstrate potential and utility of newer testing methods
- Discussions spanning preclinical safety, translational medicine to clinical trial safety & risk management
- Case studies: What works and what doesn't work
- Establishing best practices in drug development and safety
- Peer-to-peer networking and consultations
- Cutting-edge risk communication workshop

DSEC c/o Cambridge Healthtech Associates, 1000 Winter Street, Suite 3000, Waltham, MA 02451 • Phone: 781-547-0200 • Email: general@drugexecutivecouncil.org